Loading organizations...
§ Private Profile · Lansdale, PA, USA
Gene therapy company developing treatments for genetic diseases using AAvarta® and Constellation® platforms, focused on eye, CNS, and liver.
Exegenesis Bio is a clinical-stage biotechnology company developing gene therapies for eye, central nervous system, and liver diseases, operating out of offices in Philadelphia and Boston with a primary focus on the Chinese market. The organization utilizes proprietary platforms, including AAvarta for viral capsid discovery and Constellation for synthetic gene regulation, to build integrated research, development, and manufacturing capabilities. To support its advancing clinical pipeline, which includes a Phase 2 trial for Spinal Muscular Atrophy, the enterprise has hired a workforce of over 100 scientific and technical employees. The firm has raised more than $120 million in total funding from a syndicate of venture capital backers, including lead investors Legend Capital and K2 Venture Partners. Following previous roles at pharmaceutical corporations Merck & Co. and GSK, the company was officially founded in 2019 by Wu Zhenhua.
Exegenesis Bio has raised $50.0M across 1 funding round.
Exegenesis Bio has raised $50.0M in total across 1 funding round.
Exegenesis Bio has raised $50.0M in total across 1 funding round.
Exegenesis Bio's investors include Hillhouse Capital Group, CPE, Lake Bleu Capital, LYFE Capital, Temasek Holdings.
Exegenesis Bio has raised $50.0M across 1 funding round. Most recently, it raised $50.0M Series B in June 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 23, 2021 | $50M Series B | Hillhouse Capital Group | CPE, Lake Bleu Capital, Lyfe Capital, Temasek Holdings | Announced |